58R0015

Attachment to APHIS form 7023 for the University of South Florida, 1999

As required by Section 13 of the Animal Welfare Act and further explained in 9 CFR Part 2, Section 2.36, the University of South Florida submits an annual report (APHIS from 7023) to the Animal Care Regional Director, and fully explains in statements attached to this form any entries made in Column E.

In the 1998-99 annual report for this institution, 38 rabbits are listed under Column E. These animals represent two separate protocol(s).

Twenty rabbits were used in evaluations of the pharmacologic prevention and therapy of cardiomyopathy, which develops as a complication in some pediatric cancer patients treated with the chemotherapeutic drug doxorubicin. When administered to patients, doxorubicin is known to cause a reduction in their food intake. Similarily, rabbits treated with doxorubicin lose their appetite for milled chow. During this interval of anorexia, doxorubicin treatments are suspended, rabbits are fed 100 grams of fresh greens such as kale, regularly consume 25-75 grams of milled chow each day, and maintain their body weights. Pair-fed control rabbits that are not administered doxorubicin experience similar intervals of restricted food offering, but also do not lose weight. All twenty rabbits involved in this investigation are reported in Column E because this period of restricted food intake/offering could occur as part of this protocol.

Eighteen rabbits were used in evaluations of whether blocking E- and P-selectins influences therapy of ischemic paraplegia. These studies contributed to an understanding of optimal therapeutic approaches for spinal cord ischemia, injury, paresis and paralysis. All eighteen rabbits involved in this investigation are reported in Column I because the general discomfort associated with progressive paresis and/or paralysis cannot always be anticipated or thoroughly alleviated, hence the opportunity for discomfort existed as part of this protocol. Since six of these eighteen (33%) rabbits experienced clinical complications not anticipated in the written protocol including immediate post-surgical dehiscence, this investigation was closed by the IACUC, and this closure appropriately reported on April 23, 1999.

g:990190

This report is required by law (7 USC 2143) Failure to report according to the regulations can result in an order to cease and desist and to be subject to penalties as provided for in Section 2150

See reverse side for additional information

Interagency Report Control No 0180-DOA-AN

UNITED STATES DEPARTMENT OF AGRICULTURE
ANIMAL AND PLANT HEALTH INSPECTION SERVICE

1. REGISTRATION NO. ~~57-R-0023~~ 57R0023

FORM APPROVED
OMB NO 0579-0036

ANNUAL REPORT OF RESEARCH FACILITY
(TYPE OR PRINT)

880

2. HEADQUARTERS RESEARCH FACILITY *(Name and Address, as registered with USDA, include Zip Code)*

Lee Laboratories
1475 Athens Highway
Programs, University Plaza
Grayson, GA 30221
Status: Active

3. REPORTING FACILITY (List all locations where animals were housed or used in actual research, testing, teaching, or experimentation, or held for these purposes. Attach additional sheets if necessary.)

FACILITY LOCATIONS *(Sites)*

~~See Attached~~

Difco Laboratories dba Lee Laboratories

NOV 9 2 1999

EY:

REPORT OF ANIMALS USED BY OR UNDER CONTROL OF RESEARCH FACILITY *(Attach additional sheets if necessary or use APHIS FORM 7023A.)*

A. Animals Covered By The Animal Welfare Regulations	B. Number of animals being bred, conditioned, or held for use in teaching, testing, experiments, research, or surgery but not yet used for such purposes.	C. Number of animals upon which teaching, research, experiments, or tests were conducted involving no pain, distress, or use of pain-relieving drugs.	D. Number of animals upon which experiments, teaching, research, surgery, or tests were conducted involving accompanying pain or distress to the animals and for which appropriate anesthetic, analgesic, or tranquilizing drugs were used	E. Number of animals upon which teaching, experiments, research, surgery or tests were conducted involving accompanying pain or distress to the animals and for which the use of appropriate anesthetic, analgesic, or tranquilizing drugs would have adversely affected the procedures, results, or interpretation of the teaching, research, experiments, surgery, or tests. *(An explanation of the procedures producing pain or distress in these animals and the reasons such drugs were not used must be attached to this report).*	F. TOTAL NO OF ANIMALS (Cols. C + D + E)
4. Dogs					
5. Cats					
6. Guinea Pigs					
7. Hamsters					
8. Rabbits	1,283		1,153	6,945	8,098
9. Non-human Primates					
10. Sheep					
11. Pigs					
12. Other Farm Animals		(Goats) 13			13
13. Other Animals					

ASSURANCE STATEMENTS

1) Professionally acceptable standards governing the care, treatment, and use of animals, including approriate use of anesthetic, analgesic, and tranquilizing drugs, prior to, during, and following actual research, teaching, testing, surgery, or experimentation were followed by this research facility.

2) Each principal investigator has considered alternatives to painful procedures

3) This facility is adhering to the standards and regulations under the Act, and it has required that exceptions to the standards and regulations be specified and explained by the principal investigator and approved by the Institutional Animal Care and Use Committee (IACUC). A summary of all such exceptions is attached to this annual report. In addition to identifying the IACUC-approved exceptions, this summary includes a brief explanation of the exceptions, as well as the species and number of animals affected.

4) The attending veterinarian for this research facility has appropriate authority to ensure the provision of adequate veterinary care and to oversee the adequacy of other aspects of animal care and use

CERTIFICATION BY HEADQUARTES RESEARCH FACILITY OFFICIAL
(Chief Executive Officer or Legally Responsible Institutional Official)

I certify that the above is true, correct, and complete (7 U S C Section 2143)

(b)(6),(b)(7)(C)

SIGNATURE OF C.E.O. OR INSTITUTIONAL OFFICIAL [redacted]

NAME & TITLE OF C.E.O. OR INSTITUTIONAL OFFICIAL *(Type or Print)* [redacted] (b)(6) (b)(7)(C)

DATE SIGNED 11/19/99

APHIS FORM 7023 (AUG 91) (Replaces VS FORM 18-23 (OCT 88), which is obsolete)

PART 1 - HEADQUARTERS